Article Contributed by
Recently, radiation oncologist, Theresa Pagliuca, MD, board-certified radiation oncologist at WCA Hospital Cancer Treatment Center, began administering Xofigo®, a new treatment for patients with prostate cancer that has metastasized (spread) to the bones and who have failed other treatments. When prostate cancer metastasized to the bone, it can be very painful for the patient and increase the risk of fractures. WCA Hospital is the first in the region to introduce the new treatment.
Dr. Pagliuca, explains, “Xofigo is the first and only drug that involves a radioactive isotope that specifically hones in on the bones and has shown to increase the patient’s quality of life and overall survival. Once a month for six months, we inject a drug that specifically seeks out the tumors in the bones by binding to bony minerals. Xofigo mimics calcium which allows radiation delivery directly to bone tumors while minimizing damage to surrounding normal structures. What’s more, patients can continue to receive external beam radiation or CyberKnife® treatment while on Xofigo.”
Recently approved by the FDA, Xofigo is proven to alleviate symptoms of metastasized prostate cancer to the bone, thus increasing the patient’s quality of life. Importantly, this treatment was shown to increase overall survival. Its effectiveness is documented in a study published in the New England Journal of Medicine. “It’s gratifying to bring Xofigo to patients who otherwise may not have other treatment options available to them,” says Dr. Pagliuca.
For more information, or a consultation with Dr. Pagliuca at the WCA Cancer Treatment Center, call (716) 664-8670. To learn more about the WCA Cancer Treatment Center, visit wcahospital.org.